Overall, our results suggested that a high expression of RAD51, which was an oncogenic marker, was related to a poor prognostic outcome of breast cancer including shorter survival of patients and AI-resistance in neoadjuvant setting. This evidence concerns the gene RAD51 and breast carcinoma.